Moleculin Biotech stock reaches 89-patient MIRACLE milestone2d4f8a6b-9c3e-4f1a-b7d2-5e8c0a6f3b91

Published on 10/05/2026 at 11:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moleculin Biotech stock was last at USD 0.49 on October 2, 2026, after the company closed enrollment in its AML trial. Second-quarter cash stood at USD 7.262 million.

MBRX, US60855D4088, Illustration mit AI erstellt.

Moleculin Biotech (ISIN US60855D4088) was last at USD 0.49 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 3.37 percent from the prior session. The company has reached an important clinical milestone: GlobeNewswire reported on September 29, 2026 that Part A of the Phase 2/3 MIRACLE trial had closed enrollment with 89 subjects.

MIRACLE reaches its enrollment goal

The trial evaluates Annamycin combined with cytarabine in adults with relapsed or refractory acute myeloid leukemia. Moleculin said the comprehensive Part A efficacy and safety readout remains on track for the first quarter of 2027, with the analysis intended to support dose selection for Part B.

The enrollment result expands the data set beyond the first interim analysis and shifts attention toward the quality of the full randomized population. The company also said one additional subject was in screening when enrollment closed, while blinded data continued to show no cardiotoxicity in the trial, according to GlobeNewswire.

Losses remain central to valuation

For the quarter ended June 30, 2026, Moleculin reported zero revenue and a quarterly GAAP net loss of USD 7.64 million. The loss was the same as in the year-earlier quarter, while diluted GAAP loss per share was USD 1.40, according to MetaTrader.

Cash and cash equivalents stood at USD 7.262 million on June 30, 2026, against USD 6.657 million of second-quarter operating cash outflow. Moleculin also raised USD 9.3 million after the quarter, a financing cushion that management expects to support operations into the first quarter of 2027, according to StockTitan.

Analyst target stays above the quote

On September 21, 2026, H.C. Wainwright analyst Sara Nik maintained a Buy rating and a USD 3.00 price target, as reported by Markets Insider. That target lies 512.2 percent above the USD 0.49 Nasdaq price on October 2, 2026, highlighting how heavily the valuation depends on clinical execution.

The same report lists a Strong Buy consensus and an average price target of USD 12.00. For investors, the next decisive valuation test is therefore the planned 2027 data readout rather than the completed enrollment milestone alone.

MBRX stock price and trading data

Moleculin Biotech stock was last at USD 0.49 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with a 52-week range of USD 0.16 to USD 28.50, market capitalization of USD 2.6 million and volume of 422,272 shares.